SYMBRAHALE
Live / Registered — Registered (as of 07 Jan 2025)
What this means for you
Registered since 07 Jan 2025. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 07 Jan 2031: the §8 declaration of use).
Record
- Serial number
- 97408274
- Registration number
- 7637317
- Mark type
- Word mark
- Filed
- 12 May 2022
- Published for opposition
- 12 Dec 2023
- Registered
- 07 Jan 2025
- Next maintenance filing
- §8 declaration of use, due by 07 Jan 2031 (grace period to 07 Jul 2031)
- Attorney of record
- Cara M. Kearney
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment of diseases and disorders of the respiratory systems
Owner
- AstraZeneca AB, Södertälje, SE
- AstraZeneca AB, Södertälje, SE
- AstraZeneca AB, Södertälje, SE
Board proceedings on this mark
- Extension of Time to Oppose No. 97408274 — Axsome Therapeutics, Inc. v. AstraZeneca AB, filed 19 Dec 2023 (Terminated)
Prosecution history
- 07 Jan 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 07 Jan 2025 — REGISTERED-PRINCIPAL REGISTER
- 15 Oct 2024 — 1(B) BASIS DELETED; PROCEED TO REGISTRATION
- 08 May 2024 — NOTICE OF ALLOWANCE CANCELLED
- 08 May 2024 — TEAS DELETE 1(B) BASIS RECEIVED
- 23 Apr 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 14 Mar 2024 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 13 Mar 2024 — EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
- 07 Mar 2024 — POST PUBLICATION AMENDMENT - ENTERED
- 05 Mar 2024 — ASSIGNED TO PETITION STAFF
- 05 Feb 2024 — TEAS POST PUBLICATION AMENDMENT RECEIVED
- 19 Dec 2023 — EXTENSION OF TIME TO OPPOSE RECEIVED
- 12 Dec 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 12 Dec 2023 — PUBLISHED FOR OPPOSITION
- 22 Nov 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED